Posted on

MindMed Enrolls First Participant in a Study of its Session Monitoring System

MindMed Enrolls First Participant in a Study of its Session Monitoring System

NEW YORK, Jan. 18, 2021 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of mental health and addiction, today announced that it has enrolled the first subjects into its Session Monitoring System (SMS-01) study evaluating the passive collection of sensory data during a consciousness-altering therapeutic session. SMS-01 utilizes MindMed’s Session Monitoring System (MSMS), which it believes could have therapeutic applications in the treatment of psychiatric disorders.

MindMed recently consulted with the U.S. Food and Drug Administration’s (FDA) Center for Devices, Radiological Health (CDRH) and Center for Drug Evaluation and Research (CDER) and received positive feedback supporting the planned development strategy. The objective of the meeting was to review the devices Indications for Use (IFU) statement, discuss the study design and facilitate early communication and guidance through the regulatory submission process.

“We have welcomed FDA input throughout the device development process, giving us a clear roadmap for the success and adoption of MSMS,” said Daniel R Karlin, MD MA, Chief Medical Officer of MindMed. “The launch of this study is an important milestone for MindMed and for the future development of regulated devices and software-as-medical-devices (SaMD) products designed to support novel analyses of multimodal data in the delivery of psychiatric care. By refining the techniques used to capture, model and map these outputs, we aim to improve the experience of clinicians and outcomes for patients in the delivery of psychedelic and other perception-altering substances.”

“Our team has worked incredibly hard to advance this product into the clinic and we remain dedicated to rolling out these novel approaches to improving mental health outcomes,” said Todd M. Solomon, PhD, Head of Digital Psychiatry at MindMed. “We look forward to leveraging data from this study, and as we continue to advance our product development efforts, I would sincerely like to sincerely thank our team, study investigators, partners and most importantly the subjects who have agreed to participate in this study.”

About MindMed Session Monitoring System (MSMS)

MindMed Session Monitoring System (MSMS) is a technological platform and product that provides the foundation for the development and implementation of a suite of regulated and unregulated products for use by clinicians and patients during treatment sessions that may also include the use of consciousness altering medications. 

About MindMed

MindMed is a clinical-stage biopharmaceutical company developing the next generation of psychedelic-inspired therapies for the treatment of mental health and addiction. MindMed leverages rigorous drug development principles and advanced digital therapeutics to address these highly pressing, unmet patient needs. MindMed’s differentiated pipeline features innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. Led by an executive team with extensive pharmaceutical industry experience, MindMed has forged strategic collaborations with leading research and academic institutions to accelerate new medicines to patients as quickly as possible. MindMed is headquartered in New York City. For more information, please visit https://mindmed.co/.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

Media Contact: media@mindmed.co

Investor Contact: ir@mindmed.co

Posted on

Mark Haden, Clearmind Medicine’s VP of Business Development Presented at The Canadian Psychedelics Association Event

Mark Haden, Clearmind Medicine’s VP of Business Development Presented at The Canadian Psychedelics Association Event

The CPA’s Panel for physicians and medical professionals addressed “New Psychedelic Substances”

Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announces that its newly appointed VP Business Development, psychedelic medicine expert Mr. Mark Haden, presented at the Canadian Psychedelics Association (“CPA“) event, that was held earlier this week.

The event included a panel, for physicians and medical professionals only, in the topic of “New Psychedelic Substances”.

Mr. Mark Haden presented new psychedelic substances. Among other novel psychedelics, he discussed Clearmind’s innovative psychedelic candidate- MEAI, intended for alcohol-use-disorder.

Receiving an invitation from the CPA is a testimony to Mr. Haden’s expertise and knowledge of the psychedelic field. Participating in exclusive events and panels is part of the Company’s efforts to raise awareness to its innovative psychedelic treatments amongst medical professionals, industry and potential partners in North America.  


About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of two patent families. The first, “Binge Behavior Regulators”, has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute”, has been approved for a European patent, with pending applications in the U.S., China and India. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND“, the Frankfurt Stock Exchange under the symbol “CWY0.” and on the OTC pink under the symbol “CMNDF“.

For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Posted on

Clearmind Medicine Strengthens Presence in North America with New Senior Appointments

Clearmind Medicine Strengthens Presence in North America with New Senior Appointments

Mr. Mark Haden appointed to VP Business Development and Mr. Gilad Babchuk as Head of Strategy and Communication

TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce senior appointments to its management team in North America.

Mr. Mark Haden, psychedelic medicine expert, has been appointed as the Company’s Vice President Business Development. Mr. Haden was promoted to this position after serving as one of the founding members of Clearmind’s scientific advisory.

Mr. Haden has spent his career working to advance the use of psychedelics in medicine.  Mark has substantial research experience, including a leadership role in the study of Psilocybin Research Investigating Medical Efficacy, which explores psilocybin as an adjunct in the treatment of substance use disorders, and has spent 10 years as the chairman and executive director of the Multidisciplinary Association for Psychedelic Studies in Canada, an organization he founded. He has also dedicated over 25 years to working directly with patients through the Vancouver Coastal Health Addiction Services. Mr. Haden currently serves as Director of Clinical Research at Psygen Industries, a manufacturer of pharmaceutical-grade psychedelic drug products for clinical research and therapeutic applications and is an Adjunct Professor at the University of British Columbia School of Population and Public Health.

Additionally, the Company wishes to announce that, Mr. Gilad Babchuk has been appointed as the Company’s Head of Strategy and Communication. Mr. Babchuk is a serial entrepreneur with 28 years of global experience in establishing, developing, and running organizations. He served as a strategic advisor to top-level managers in both the private and public sectors as well as to certain politicians at various governmental levels.  He was a founder and co-founder of over 15 social ventures, as well as a 4-time CEO. Gilad is an acclaimed speaker and is currently a consultant for multinational companies, working with senior CEOs, business leaders, and entrepreneurs worldwide.

Dr. Adi Zuloff-Shani, Ph.D., CEO of Clearmind, commented on the announcement, “As we continue to increase our footprint in North America, I am excited to welcome our newest team members. Since joining our scientific advisory board, Adjunct Prof. Haden’s contributions have been plentiful and we believe that as VP of Business Development, his expertise and connections will greatly improve the future progression of the company.”

“Mr. Babchuk has decades of experience in taking companies to their next stage with well-established strategies and tactics. I am confident that our new team members will support Clearmind in achieving its goals for the upcoming year and will facilitate efforts in North America,” Zuloff-Shani added.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of four patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND“, the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC pink under the symbol “CMNDF“.

For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

‍

Posted on

Stephen Hurst Resigns from MindMed Board of Directors

Stephen Hurst Resigns from MindMed Board of Directors

NEW YORK, January 7, 2022 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-derived therapies, announces the resignation of Stephen Hurst from his role as a Director of the Company’s Board of Directors.

“On behalf of MindMed, the Board of Directors, and the Executive team, I thank Steve for his significant contributions and strategic guidance in bringing the Company to this stage of development,” said Robert Barrow, Chief Executive Officer and Director of MindMed. “The co-founders and early leadership of MindMed have been instrumental in establishing the Company and its strong foundation. Their work, vision, and the programs that they initiated will continue to serve as the basis for our execution of the Company’s mission. As we approach important milestones across our clinical development programs, we are extremely grateful for Steve’s effort to enable this progress.” 

Mr. Hurst added “MindMed is the culmination of my career and more than a decade of work to bring the benefits of psychedelic-inspired medicines to patients struggling with addiction and mental illness. With the recent appointment of two seasoned Directors and a brilliant Chief Executive Officer, I have the greatest confidence in the team’s ability to guide the Company through this next phase of continued progress toward the realization of our highest aspirations.”

About MindMed

MindMed is a clinical-stage biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address mental health and addiction. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed’s approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

For Media: media@mindmed.co

For Investors: ir@mindmed.co

Posted on

Finally, a way to have less sex in 2022: issue 31

Hello and welcome back.

We hope you’ve had a great start to 2022. 

In 2021, we read thousands of articles so you didn’t have to. (You’re welcome 😉)

We curated the best content and summarized over 300 articles so you could be the smartest mushroom in the room, covering over 45 conditions and disorders that could potentially be treated with psychedelics 🤯 

This is just the beginning… Get ready for another year of groundbreaking research, inspiring stories, and major business deals. 

Here’s what’s in store for you in today’s issue:

🍄 Take a psychedelic retreat from your bed

🍄 The African shrub that could solve the opioid crisis

🍄 How to make your NY’s resolutions stick

🍄 How psychedelic therapy just got A LOT more accessible for Canadians

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

What physicians really think about psilocybin

On this episode of the Daily Mushroom Podcast, we have Dr. Lyle Oberg, co-founder, and CEO of MYND life sciences. Dr. Oberg has been had an extensive career across many sectors, including working as a family physician and a Chief Policy and Medical Officer at a cannabis company. He was also part of the Alberta government for 15 years as Minister of Finance, Social Services, Learning, and more. Stick around to hear what Dr. Oberg has to say, we are sure it will give a new insight into the world of psychedelics!

Therapeutic banner

Microdoses for the whole family

Here’s a fun way to bond with grandma…

Mindset Pharma (MSET) filed a patent for psilocybin microdoses that have potential to treat Alzheimer’s disease and ADHD. 

The compounds may promote cognitive benefits without the liability of a psychedelic experience, making them suitable for “fragile population groups” like children and the elderly, according to the company’s Chief Scientific Officer.

Could this African shrub solve the opioid crisis?

MindMed (MNMD) developed a non-hallucinogenic molecule based on ibogaine, the psychoactive compound in the African iboga plant, and it’s showing potential to treat opioid addiction.

How? 🤔

The compound has demonstrated the ability to reduce opioid use and ease withdrawal symptoms by regulating excessive dopamine fluctuations.

An upcoming Phase 2a trial will put the compound to the test.

Make your New Year’s resolutions stick

Spent too much time gaming or had too much sex in 2021? 

We’re guessing you didn’t answer yes to both, but if you struggle with one of these things, ketamine therapy could help you make changes this year 😉

Awakn Life Sciences (AWKN) received ethics approval to expand its ketamine study. In addition to investigating Gambling Disorder, it will now cover three more behavioral addictions: Internet Gaming Disorder, Compulsive Sexual Behaviour, and Binge Eating Disorder.

The goal is to “harness a window in which the brain is able to make new connections” to create lasting behaviour changes. 

inspirational banner

The quest to treat addiction

After his brother overdosed in 2019, Timothy Ko founded Entheon Biomedical (ENBI) on his quest to find a better treatment for addiction through psychedelic therapy.

The company is focused on advancing the DMT molecule to treat substance use disorders. It just submitted a regulatory package to an ethics committee for a human clinical trial on healthy smokers, which will be one of the most comprehensive studies of DMT ever.

Entheon has also begun recruiting patients with treatment-resistant depression for a ketamine therapy study, which will be conducted with Heading Health LLC. The study will use an electroencephalography (EEG) headset and genetic screening to:

  • Understand how ketamine influences brainwave patterns
  • Investigate how genetic markers influence ketamine response
  • Explore the effects of music on therapeutic outcomes
  • Develop a framework for characterizing the psychedelic drug state

Take a psychedelic retreat from your bed

Psychedelic retreats are inaccessible to most due to high costs, length of treatments, and travel restrictions. Who has ten thousand dollars to drop on a week in Jamaica?

That’s why Ei.Ventures is investing (heavily) in the Metaverse.

The company purchased a $2.2M estate in The Sandbox virtual world – the third largest land sale in the Metaverse ever. 

The goal? 

To provide “wondrous” psychedelic journeys through the Hawaiian islands, or outer space, using VR technology.

Sound like the ideal setting for your next trip?

business banner

Filament Health (FH) received Health Canada approval for a psilocybin microdosing study on 100 patients with persistent depression, which will be funded by the Nikean Foundation.

The McQuade Centre for Strategic Research and Development (MSRD), a subsidiary of Otsuka Pharmaceutical (one of Japan’s biggest pharma companies), invested $5M in Mindset Pharma to support its drug development.

MindBio Therapeutics is aiming to develop a “smart drug delivery technology” that can use patient data to determine an optimal microdose for each individual.

Compass Pathways’ (CMPS) early psilocybin research was published in The Journal of Psychopharmacology this week. The study suggests that both low and high doses of psilocybin are safe to administer in group settings and do not have negative impacts on thought patterns or processing of emotions. 

legal banner

Psychedelic therapy just got A LOT more accessible for Canadians

Until now, the only way for patients to access psychedelic therapy outside a clinical trial was to apply for a Section 56 exemption and wait months on end to (possibly) receive approval from Health Canada.

Despite six more patients receiving the exemption over the holidays, the system remains flawed.

Thankfully, this Wednesday, Health Canada made an amendment to this thing called the Special Access Program (SAP), which enables healthcare practitioners to request access to drugs that are not yet approved, but have shown promise in clinical trials.

The amendment allows practitioners to request access to psilocybin and MDMA for their patients with serious, life-threatening, or treatment-adverse conditions. And the best part: requests are typically processed in just 1 day! 🎉

While this does not guarantee access for patients, it certainly feels like a big step in the right direction.

To learn more about the amendment, check out TheraPsil’s free webinar on Jan. 19th.

WA pushes for psilocybin sessions for all

Washington State legislators introduced a bill that would legalize supported psilocybin sessions for “nearly any purpose” – no medical diagnosis required.

The experiences would be administered by state-licensed facilitators at licensed service centers or, in some cases, remotely.

Goodbye styrofoam 👋

M2Bio Sciences developed a sustainable alternative to styrofoam out of mushroom mycelium and hemp. 

The foamy material, appropriately named Hempcelium, is fully biodegradable and can even remove industrial toxins from groundwater and soil.

Plus, it takes less energy to produce than styrofoam and can be grown into any shape.

Video of the Week

Meet The Mushroom Hermit of The Carpathians

Playlist of the Week

Psychedelic Chill
Posted on

Could this African shrub solve the opioid crisis?

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

MindMed (MNMD) developed a non-hallucinogenic molecule based on ibogaine, the psychoactive compound in the African iboga plant, and it’s showing potential to treat opioid addiction.

How? 🤔

The compound has demonstrated the ability to reduce opioid use and ease withdrawal symptoms by regulating excessive dopamine fluctuations.

An upcoming Phase 2a trial will put the compound to the test.

PDF of article

Posted on

2021 Psychedelics Unwrapped // 2022 Year of the 🍄: issue 30

Hello and welcome back for the final issue of the year.

2021 proved to be a monumental year for the psychedelic sector. We saw more psychedelic research than ever before, and the medicines became widely accepted by the public and mainstream media (we like to think that we helped with that 😉).

In this special issue, we’ll review this year’s top advancements, scientific breakthroughs, and legislation changes that have moved the psychedelic revolution forward.

Whether you’ve been following along since Issue 1 or you’re brand new to the Daily Mushroom Community – thank you for joining us 🧡 We are so grateful that we can use this platform to give psychedelic medicine the attention it deserves. 

We’ll see you in the New Year with an exciting announcement!

Don’t miss a Daily Mushroom Podcast!

 In 2021, we heard stories from:

  • The first Canadian to receive legal psilocybin therapy
  • CEOs of major psychedelic companies
  • The founder of a ketamine-assisted group therapy workshop
  • A veteran who cured his pain and PTSD with a (wild) DMT trip
  • And many more amazing guests

Listen now on YouTube, Spotify, or Apple ⬇️

Therapeutic banner

MDMA was found to be an extremely promising PTSD treatment

The Multidisciplinary Association for Psychedelic Studies (MAPS) conducted the first-ever Phase 3 trial for psychedelic-assisted therapy – and the results were incredible.

Patients with chronic PTSD (many battling the condition for over 20 years) finally found relief after three sessions of MDMA-assisted therapy.

Of the 46 patients, two-thirds no longer qualified for a PTSD diagnosis and 88% experienced a clinically significant reduction in symptoms after the sessions 👏

Researchers explain that MDMA reduces activity in the amygdala, a part of the brain associated with fear response, allowing patients to process trauma in therapy without becoming overwhelmed.

MAPS expects that MDMA therapy will become FDA-approved in 2023. The non-profit has begun patient enrollment for a second study of similar nature, so stay tuned for the results.

Psilocybin out-performed a leading antidepressant…

A study conducted by Dr. Robin Carhart-Harris at Imperial College London suggests that psilocybin is more effective than antidepressants – and with fewer side effects.

Patients with mild-to-severe depression were given either a daily dose of escitalopram (aka Lexapro) or two doses of psilocybin. 

In the psilocybin group:

  • 70% saw at least a 50% reduction in depression scores, with an average decrease of 8.0 points
  • 57% were in remission at week 6, meaning they no longer qualified for a depression diagnosis
  • Patients were more likely to report improvements in the ability to feel compassion, pleasure, and intense emotion
  • No patient requested to stop dosing
  • The most common adverse event was headache

In the escitalopram group:

  • 48% saw at least a 50% reduction in depression scores, with an average decrease of 6.0 points
  • 28% were in remission from depression at week 6
  • Patients were more likely to experience anxiety, dry mouth, sexual dysfunction, drowsiness, and reduced emotional responsiveness
  • 4 patients stopped dosing and 1 halved their dose due to adverse side effects 

…and became widely accepted as viable treatment

These magazine covers say it all – just look how far we’ve come!

Research revealed that psychedelics help the brain grow

Yale researchers discovered that psilocybin regrows and strengthens neuronal connections that can be lost due to depression or chronic stress.

Two months later, Algernon Pharmaceuticals (AGN) found that DMT was even more effective at growing neuronal connections, even at sub-hallucinogenic doses 🤯

The formation of new connections could explain why psychedelics are so effective at altering negative thought patterns and fostering positive behaviour change!

inspirational banner

Psychedelic research received gov’t funding for first time in 50 years

When the War on Drugs was declared in the 70s, the US federal government stopped funding psychedelic research. 

Things changed this September, when Johns Hopkins researcher Dr. Matthew W. Johnson received a grant from the National Institute on Drug Abuse (NIDA) to conduct a psilocybin study on tobacco addiction.

So far, his research has suggested that psilocybin is more than twice as effective at treating addiction than nicotine patches.  

The Canadian government also began funding psilocybin research, with a grant given to MYND Life Sciences (MYND) to study depression and neuroinflammation.

Canada expanded access to psilocybin therapy 🇨🇦

Earlier this month, three Canadians gained legal exemptions to access psilocybin therapy to treat mental health conditions. This marked an exciting turning point by expanding access to the treatment beyond end-of-life care.

DMT was fast-tracked in the UK 🇬🇧

In October, Small Pharma’s DMT program for depression was found to be so promising that it was granted an Innovation Passport Designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

The designation will give Small Pharma access to specialist advice to expedite the drug development process and facilitate patient access to the treatment.

Once approved, DMT could make psychedelic therapy more accessible and affordable because the trip takes just 20 minutes, yet produces long lasting effects!

Microdosing took the world by storm 💊

We saw an explosion of microdosing research this year, including the largest psychedelic study to date, which revealed that microdosers exhibit lower levels of depression, anxiety, and stress than non-microdosers. Many other intriguing studies have been initiated such as:

business banner

Companies around the world jumped on the psychedelic bandwagon

With more and more research confirming the incredible healing power of psychedelics, it’s no surprise that we’ve seen a tremendous amount of capital invested in the sector this year. 

At the beginning of the year, there were just a handful of publicly-traded psychedelic companies.  Now, there are over 70 public companies working to bring psychedelic medicines to market – some valued at over $1 billion! 🚀

The first-ever psychedelic indexes were launched

In 2021, it became easier than ever to diversify your psychedelic portfolio 🤑

In January, Horizons ETFs Management debuted PSYK on Toronto’s NEO exchange, becoming the first exchange traded fund for psychedelic stocks.

Later in the year, two more ETFs were introduced on US exchanges – Definace ETFs’ PSY, a passive fund, and AdvisorShares’ PSIL, an actively managed fund.

Private investments reached record highs

Private investments in psychedelic companies reached $595M across 45 deals this November —  that’s an increase of 66% from last year and 625% higher than in 2019 📈

legal banner

We saw widespread drug reform across both red and blue states…

Some or all psychedelics were decriminalized in:

More big wins:

  • Texas and Connecticut passed bills to study the therapeutic potential of psilocybin.
  • New Jersey successfully reduced the criminal penalties for possession of psilocybin.
  • The DEA increased production quotas for psilocybin, psilocin, MDMA, and DMT for both 2021 and 2022, allowing more research to be conducted.

We saw widespread drug reform across both red and blue states…

Legislation was filed to decriminalize psychedelics in:

Legislation was filed to promote psychedelic research or legalize therapeutic use in:

Posted on

MindMed to Participate at the LifeSci Partners 11th Annual Corporate Access Event

MindMed to Participate at the LifeSci Partners 11th Annual Corporate Access Event

NEW YORK, December 30, 2021– Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed’s Chief Executive Officer and Director, Robert Barrow, will be participating in a panel and in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022.

Details on the panel discussion can be found below. 

Topic: “Psychedelics: More Than Just a Trip”

Date: Wednesday, January 5, 2022

Time: 10:00 AM ET

Webcast link: Click Here 

A replay link of the panel discussion will also be available on MindMed’s website. 

About MindMed

MindMed is a clinical-stage biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address mental health and addiction. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed’s approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

For Media: media@mindmed.co

For Investors: ir@mindmed.co

Posted on

MindMed Announces Transitions to Management Team

MindMed Announces Transitions to Management Team

– Bradford Cross, Chief Technology Officer to transition; Don Gehlert, PhD, Chief Scientific Officer to transition to Senior Scientific Advisor –

NEW YORK, December 29, 2021 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, today announced that its Chief Technology Officer, Bradford Cross, has transitioned from his role.

“On behalf of the Board of Directors and Executive team, I would like to thank Bradford for his contributions to the Company and wish him all the best in his future endeavors,” said Robert Barrow, Chief Executive Officer and Director of MindMed. “We remain dedicated to advancing our pipeline and ongoing digital therapeutics platform forward under the leadership of MindMed Chief Medical Officer, Dr. Daniel Karlin. We enter 2022 well positioned both financially and strategically to continue on our mission to transform mental health treatment.”

Additionally, Don Gehlert, PhD will be transitioning from his role as CSO and will continue as a Senior Scientific Advisor.  Mr. Barrow added “Don has been and will continue to be an integral part of our organization.  While this represents a change in his title, our entire team will continue to work closely with Don and benefit from his incredible breadth of experience in developing innovative CNS therapeutics.”

About MindMed

MindMed is a clinical-stage biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed’s approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws and regulations. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Forward-looking information in this news release include, but are not limited to, statements regarding future relationship or involvement of the Company’s Senior Scientific Advisor. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including changes in the relationship with the Company’s Senior Scientific Advisor. Further information regarding these and other risks, uncertainties or factors is described under the headings “Risk Factors” included in the Company’s filings with the Canadian securities regulators on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

For Media: media@mindmed.co

For Investors: ir@mindmed.co

Posted on

Clearmind Medicine Launches Study for Binge Eating with The Hebrew University Using its Proprietary MEAI Compound

Clearmind Medicine Launches Study for Binge Eating with The Hebrew University Using its Proprietary MEAI Compound

‍Focus on the discovery and development of novel therapeutic strategies to treat obesity and its related metabolic disorders

TORONTO, Nov. 24, 2021 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF), (“Clearmind” or the “Company”), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce it has signed an agreement to fund a new research and development project with the Hebrew University of Jerusalem’s Obesity and Metabolism Laboratory, to evaluate the Company’s proprietary compound, MEAI’s direct effect on binge eating including food and water intakes as well as activity and metabolic parameters.

The study, which will be overseen by Prof. Joseph (Yossi) Tam, D.M.D., Ph.D., head of the Obesity and Metabolism Laboratory and Associate Professor of Pharmacology at the Hebrew University’s Institute for Drug Research, will focus on testing the potential of MEAI to treat binge eating and related behaviors, and will support the discovery and development of novel therapeutic strategies to safely treat obesity and its associated metabolic disorders.

Increasingly prevalent in developed nations, the conditions of being overweight and obese are a serious health concern as they contribute to so many other conditions, including heart disease, stroke, type 2 diabetes, fatty liver disease, and certain types of cancers, some of the leading causes of preventable, premature death in the US. The Center for Disease Control and Prevention estimates that about 74% of adults in the US are overweight1 and over 40% are considered obese2. According to a recent study published in 2020, this phenomenon is also accompanied with the high and rising costs of obesity to the US Health Care system at an estimated annual medical cost for the full non-institutionalized population of adults, in 2013, equaling $342.2 billion.

Adi Zuloff-Shani, Ph.D., CEO of Clearmind, commented on the announcement, “The medical community has yet to establish an effective therapeutic or preventative treatment for obesity, despite its increasing prevalence and severe negative impacts on the medical and economic health of people around the world. Clearmind has been able to demonstrate the positive influence MEAI has on binge behavior with regard to alcohol use, and our preliminary research indicates it may have a similar effect on metabolic disorders.”

Prof. Tam added, “I have spent my career exploring the biological mechanisms underlying obesity and the metabolic syndrome, intending to develop an effective drug therapy. After viewing the early data on MEAI, I am optimistic that this compound has the potential to be a building block for a real solution and look forward to working with the Clearmind team to advance our shared objective.”

The first phase of the three-stage study will focus on assessing the direct effect of MEAI on food and water intakes as well as its ability to modulate activity and metabolic parameters.

Following the initial screening, the study will evaluate MEAI’s efficacy as a therapeutic metabolic agent on a high-fat diet-induced obese mouse model, by measuring MEAI’s potential to treat obesity, hepatic injury, glycemic and hormonal imbalance. Lastly MEAI’s binge eating and drinking mitigating properties will be determined by comparison of cumulative food and sucrose preference, respectively.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of four patent families. The first, “Binge Behavior Regulators”, has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute”, has been approved for a European patent, with pending applications in the U.S., China and India. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND“, the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC Pink under the symbol “CMNDF“.

For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (778) 400-5347
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include discussion of the new research and development project with the Hebrew University of Jerusalem’s Obesity and Metabolism Laboratory and the benefits of product candidate. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.